8-K: Salarius Pharmaceuticals Amends Decoy Therapeutics Merger Terms to Facilitate Preferred Stock Conversion

Salarius Pharmaceuticals, Inc. has entered into a Fourth Amendment to its merger agreement with Decoy Therapeutics Inc., modifying preferred stock conversion terms to secure holder consent and facilitate the merger.

Summary

• Salarius Pharmaceuticals, Inc. (Salarius) and Decoy Therapeutics Inc. (Decoy) executed a Fourth Amendment to their Agreement and Plan of Merger, originally dated January 10, 2025.
• The amendment, effective July 29, 2025, modifies the conversion terms of Salarius's Series A and Series B Non-Voting Convertible Preferred Stock.
• The primary goal of these modifications is to induce consent and conversion from holders of certain convertible and non-convertible notes of Decoy.
• Key changes to the Preferred Stock conversion terms include removing the $2 million threshold for subsequent financing adjustments, changing the conversion price adjustment from weighted average to actual per share offering price in subsequent financings, and eliminating the one-year limitation on conversion ratio adjustments.
• Adjustments to the conversion ratio will now apply until stockholder approval for conversion and satisfaction of Nasdaq initial listing standards are met.
• The conversion ratio for each share of Preferred Stock is 1,000 shares of Common Stock.
• Conversion of Preferred Stock is contingent upon obtaining stockholder approval and meeting Nasdaq initial listing conditions.
• A beneficial ownership limitation is set at 4.99% of outstanding Common Stock, adjustable up to 9.99% with notice, but not exceeding 19.99%.
• Holders of Preferred Stock are prohibited from short selling or hedging Common Stock.

Sentiment

Score: 6

Explanation: The filing indicates progress in resolving complex aspects of the merger by adjusting preferred stock terms to secure stakeholder consent. While it addresses a necessary step, the need for a fourth amendment suggests ongoing complexities. The terms aim to facilitate the merger, which is generally positive, but the restrictions on conversion until specific conditions are met introduce some uncertainty for preferred holders.

Positives

• The amendment facilitates the ongoing merger with Decoy Therapeutics by inducing consent and conversion from noteholders, which is crucial for the transaction's progression.
• Removal of the $2 million threshold for subsequent financing adjustments and the one-year limitation on conversion ratio adjustments provides greater flexibility and potentially more favorable terms for preferred stock holders, which could aid in securing their consent.
• The change to actual per share offering price for conversion adjustments in subsequent financings may offer more transparent and potentially beneficial terms for preferred stock holders.

Negatives

• The need for a fourth amendment suggests complexities or challenges in finalizing the merger terms, potentially indicating difficulties in aligning stakeholder interests.
• The beneficial ownership limitation (initially 4.99%, max 19.99%) restricts the immediate convertibility of preferred shares into common stock, potentially limiting liquidity for holders until stockholder approval and Nasdaq listing conditions are met.
• A 'Share Cap' of zero shares for conversion until Stockholder Approval and Nasdaq Conversion Condition are met means preferred stock cannot be converted into common stock immediately, which could be a negative for holders seeking liquidity.

Risks

• Failure to obtain Stockholder Approval for the conversion of Preferred Stock could impede the full conversion of preferred shares into common stock.
• Failure to satisfy the Nasdaq Conversion Condition (initial listing on Nasdaq or another national securities exchange) would also prevent the full conversion of Preferred Stock.
• The ongoing need for amendments to the merger agreement could signal underlying complexities or potential for further delays in the merger's completion.
• Future equity sales (Subsequent Financing) at a price lower than the S-1 Financing price could trigger a reset of the conversion ratio, potentially diluting the value for existing common stockholders.
• The mandatory redemption of Series B Preferred Stock using proceeds from the At the Market (ATM) Program or Equity Line of Credit (ELOC) could impact the company's cash flow or future capital raising flexibility.

Future Outlook

The full conversion of the Preferred Stock into Common Stock is contingent upon obtaining stockholder approval and meeting Nasdaq initial listing standards. The elimination of the one-year limitation on conversion ratio adjustments indicates that these adjustments will continue until these conditions are satisfied, suggesting a long-term view towards the merger's full integration and compliance with listing requirements.

Industry Context

This amendment reflects a common challenge in biotech and pharmaceutical mergers, where complex capital structures and diverse stakeholder interests (e.g., noteholders, preferred shareholders) often necessitate detailed negotiations and adjustments to ensure deal completion. The focus on preferred stock conversion and Nasdaq listing compliance is typical for smaller, development-stage companies undergoing strategic transactions to ensure market access and liquidity post-merger.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for dilution from future conversions of preferred stock, especially if subsequent financings occur at lower prices. The beneficial ownership limitation aims to manage immediate dilution.
• Preferred Stock Holders (Series A & B): Conversion terms are modified to induce their consent, potentially offering more favorable or clearer conversion mechanics. However, conversion is still contingent on stockholder approval and Nasdaq listing, and there are beneficial ownership limitations.
• Decoy Therapeutics Noteholders: The amendment is specifically designed to induce their consent and conversion, suggesting improved terms or clarity for them to participate in the merger.
• Company (Salarius Pharmaceuticals): The amendment helps progress the merger, which is a strategic objective. It also outlines mechanisms for future capital management (redemption of Series B).

Next Steps

• Obtain Stockholder Approval for the conversion of Preferred Stock.
• Satisfy the Nasdaq Conversion Condition (initial listing on Nasdaq Stock Market or another national securities exchange).
• Complete the merger with Decoy Therapeutics Inc.
• Redeem Series B Preferred Stock using proceeds from ATM Program or ELOC drawdowns.

Key Dates

Recommendation

The filing details a necessary amendment to a merger agreement, indicating progress in a complex transaction. While the modifications aim to facilitate the merger by inducing consent from noteholders, the underlying complexities that necessitated a fourth amendment suggest continued uncertainty. The stock's performance will largely depend on the successful completion of the merger, obtaining stockholder approval, and meeting Nasdaq listing requirements. Until these significant milestones are achieved, a 'hold' recommendation is appropriate, as the immediate impact is on the mechanics of the deal rather than direct operational or financial performance.

Keywords

Salarius Pharmaceuticals, Decoy Therapeutics, Merger Agreement, SEC Filing, 8-K, Preferred Stock, Convertible Securities, Corporate Governance, Nasdaq Listing, Stockholder Approval, Biotechnology, Pharmaceuticals, M&A, Equity Financing